Sage Journals: Discover world-class research

Abstract

Objective:

We compared economic outcomes when elderly patients with neuropsychiatric disorders received psychotropic medications guided by a combinatorial pharmacogenomic (PGx) test.

Methods:

This is a subanalysis of a 1-year prospective assessment of medication cost for patients with neuropsychiatric disorders receiving combinatorial PGx testing. Pharmacy claims were used to compare per member per year (PMPY) medication cost for patients ≥65 and <65 years old when medications were congruent or incongruent with the PGx test. Polypharmacy was also assessed.

Results:

Congruent prescribing was associated with savings of US$3497 PMPY (P < .001) for patients ≥65 years and US$2467 PMPY (P < .001) for patients <65, compared to incongruent prescribing. Congruent prescribing in patients ≥65 treated by primary care providers was associated with US$4113 PMPY (P = .026) in savings, while congruent prescribing by psychiatrists was associated with US$120 PMPY (P = .719). Congruent prescribing was also associated with one fewer neuropsychiatric medication for patients ≥65 (P = .070).

Conclusion:

Congruence with PGx testing was associated with medication cost savings in elderly patients.

Keywords

depression anxiety pharmacotherapy genetics geriatric psychiatry elderly GeneSight combinatorial pharmacogenomics

Get full access to this article

View all access options for this article.

References

National Institute of Mental Health. Mental Health Information: Statistics. https://www.nimh.nih.gov/health/statistics/index.shtml. Accessed December 6, 2016.

Rush

Trivedi

Wisniewski

, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.

Mrazek

Hornberger

Altar

Degtiar

. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014;65(8):977–987.

Warden

Rush

Trivedi

Fava

Wisniewski

. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449–459.

Jones

Macias

Barreira

Fisher

Hargreaves

Harding

. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv. 2004;55(11):1250–1257.

Altar

Carhart

Allen

Hall-Flavin

Dechairo

Winner

. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015;15(5):443–451.

Hall-Flavin

Winner

Allen

, et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172.

Hall-Flavin

Winner

Allen

, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23(10):535–548.

Winner

Carhart

Altar

Allen

Dechairo

. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16(89):219–227.

10.

Winner

Allen

Altar

Spahic-Mihajlovic

. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242.

11.

Winner

Carhart

Altar

, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31(9):1633–1643.

12.

Tanner

Davies

Voudouris

, et al. Combinatorial pharmacogenomics and improved patient outcomes in depression: treatment by primary care physicians or psychiatrists. J Psychiatr Res. 2018;104:157–162.

13.

Greden

Parikh

Rothschild

, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59–67.

14.

Brown

Lorenz

Dechairo

. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clinical Therapeutics. 2017;39(3):592–602.e591.

15.

Centers for Medicare & Medicaid Services. Total Medicare Enrollment: Part A and/or Part B Enrollees, by Age Group, Calendar Years 2008-2013. Research Statistics, Data, and Systems; 2013. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMSProgramStatistics/2013/Downloads/MDCR_ENROLL_AB/CPS_MDCR_ENROLL_AB_4.pdf. Accessed December 21, 2013.

16.

Centers for Medicare & Medicaid Services. Description of antipsychotic medication quality measures on nursing home compare. Provider Enrollment and Certification. 2016. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandComplianc/Downloads/AntipsychoticMedicationQM.pdf. Accessed December 21, 2016.

17.

Chiu

Bero

Hessol

Lexchin

Harrington

. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015;119(6):802–813.

18.

Lenze

Ajam Oughli

. Antidepressant treatment for late-life depression: considering risks and benefits. J Am Geriatr Soc. 2019;67(8):1555–1556.

19.

Medco. Formulary Reference Guide . 2012. https://host1.medcohealth.com/art/corporate/medco_formularies.pdf. Accessed December 6, 2016.

20.

Dhavale

Panikkar

Jadhav

Ghulghule

Agari

. Depression and diabetes: impact of antidepressant medications on glycaemic control. J Assoc Physicians India. 2013;61(12):896–899.

21.

Lustman

Clouse

Nix

, et al. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(5):521–529.

22.

Echeverry

Duran

Bonds

Lee

Davidson

. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2009;32(12):2156–2160.

23.

Abrahamian

Hofmann

Kinzl

Toplak

. Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus Study group). Neuropsychiatr Dis Treat. 2012;8:355–360.

24.

Pinquart

Duberstein

. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797–1810.

25.

Lloyd-Williams

Shiels

Taylor

Dennis

. Depression—an independent predictor of early death in patients with advanced cancer. J Affect Disord. 2009;113(1-2):127–132.

26.

Sareen

Jacobi

Cox

Belik

Clara

Stein

. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006;166(19):2109–2116.

27.

Niles

Dour

Stanton

, et al. Anxiety and depressive symptoms and medical illness among adults with anxiety disorders. J Psychosom Res. 2015;78(2):109–115.

28.

Comer

Blanco

Hasin

, et al. Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC). J Clin Psychiatry. 2011;72(1):43–50.

29.

Thomas

Ellis

Konrad

Holzer

Morrissey

. County-level estimates of mental health professional shortage in the United States. Psychiatr Serv. 2009;60(10):1323–1328.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.14 MB

Economic Outcomes Following Combinatorial Pharmacogenomic Testing for Elderly Psychiatric Patients

Abstract

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material